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Abstract:  
Introduction: Psoriasis is a chronic skin disorder associated with several 
comorbid conditions. In psoriasis pathogenesis, the role of some cytokines, 
including TNF-α and IL-17, has been elucidated. Beside their pro-inflammatory 
activity, they may also affect glucose and lipid metabolism, possibly promoting 
insulin resistance and obesity. On the other hand, adipose tissue, secreting 
adipokines such as chemerin, visfatin, leptin, and adiponectin, not only regulates 
glucose and lipid metabolism, and endothelial cell function regulation, but it may 
contribute to inflammation.  
Areas covered: This review provides an updated “state-of-the-art” about the 
reciprocal contribution of a small subset of conventional cytokines and 
adipokines involved in chronic inflammatory pathways, upregulated in both 
psoriasis and increased adiposity. A systematic search was conducted using the 
PubMed Medline database for primary articles. 
Expert Commentary: Because psoriasis is associated with increased adiposity, it 
would be important to define the contribution of chronic skin inflammation to 
the onset of obesity and vice versa. Clarifying the pathogenic mechanism 
underlying this association, a therapeutic strategy having favorable effects on 
both psoriasis and increased adiposity could be identified. 
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1.0 Introduction 
Psoriasis is a chronic inflammatory skin disease affecting about 2.5% of the 
population worldwide [1]. In genetically predisposed subjects, environmental or 
endogenous stimuli trigger the onset of the disease, characterized by an altered 
immune activation and an aberrant keratinocyte proliferation [2]. Substantial 
evidence recognized an association between psoriasis and various comorbid 
conditions including arthritis, osteoporosis, non alcoholic fatty liver disease, 
increased spleen longitudinal diameter, cardiovascular diseases, and metabolic 
syndrome, which constitutes a cluster of disorders ranging from hypertension, 
central obesity, atherogenic dyslipidemia, and glucose intolerance [3-5]. Patients 
suffering from psoriasis showed an increased risk of developing metabolic 
syndrome [6-12]. A higher prevalence of metabolic syndrome was observed in a 
psoriasis population adjusted for age, sex, race/ethnicity, smoking, and C-
reactive protein level [13]. The biologic mechanism is not fully understood, 
though some pathogenic links between these two disorders have been identified. 
Firstly, some genetic loci represent susceptibility factors (PSORS2-4, CDKAL1, 
and ApoE4) for both psoriasis and metabolic syndrome [14,15]. Additionally, 
Western dietary pattern is included among the environmental dietary factors 
involved in the pathogenesis of both disorders. Differences in dietary intake 
were observed in adult male psoriatic patients compared to controls. These 
differences were associated to the severity of psoriasis and cardio-metabolic risk 
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[16,17]. In obese psoriatic patients, an energy-restricted diet designed to 
increase n-3 and to reduce n-6 polyunsaturated fatty acids (PUFAs), ameliorated 
the metabolic profile and, by increasing the response to immuno-modulating 
therapy, improved the clinical outcomes of the disease [18]. Moreover, metabolic 
syndrome is characterized by a state of chronic systemic inflammation sustained 
by the adipose tissue, that is not a mere inert fat storage but an endocrine organ 
secreting multiple mediators, named “adipokines”, contributing to inflammation, 
as well as to glucose and lipid metabolism, and endothelial cell function 
regulation [19]. Traditionally, two types of adipose tissue are recognized: brown 
adipose tissue (BAT), associated with energy expenditure as well as 
thermogenesis and white adipose tissue (WAT), responsible for energy storage 
[20]. In addition to adipocytes, adipose tissue also contains endothelial cells, 
fibroblasts, macrophages, myeloid cells and T cells [21]. In a lean state, T helper 
(h)2 cells, T regulatory (reg), Breg, and invariant natural killer (NK)T cells are 
the dominant cell population in WAT [22,23]; in contrast, augmented adiposity 
results in increased number of pro-inflammatory immune cells, including Th1 
and Th17 cells [22,24]. Adipokines are able to orchestrate the interaction 
between metabolic and immune systems. The wide array of adipokines, secreted 
by the adipose tissue, includes at least 50 bioactive molecules [25], not all 
exclusively produced by adipocytes. In particular, resident macrophages 
contribute to the production of some cytokines and chemokines such as 
interleukin (IL)-1β, IL-6, Tumor necrosis factor (TNF)-α and monocyte 
chemotactic protein(MCP)-1 [26], while more conventional adipokines, such as 
adiponectin, leptin, visfatin, chemerin, plasminogen activator inhibitor type 1 
(PAI-1), are mostly released by adipocytes. Either the mediators released by 
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adipocytes or by other cells resident in the adipose tissue, may play an important 
role in multiple autoimmune skin diseases, acting on immune cells and 
keratinocytes (Table 1) [27-45] . Notably, TNF-α is highly expressed in both 
psoriasis and obesity [46], and similarly, other adipokines (i.e., IL-6 and leptin) 
are known as proinflammatory mediators and may contribute to psoriasis 
inflammation [3]. Meanwhile, the same pro-inflammatory mediators (i.e., TNF-α 
and IL-6) may (i) impair glucose metabolism, inducing insulin resistance, or they 
may lead to (ii) endothelial dysfunction, (iii) altered lipid metabolism, (iv) 
hypertension, and (v) enhanced risk of cardiovascular diseases [46]. However, in 
a context of chronic adipose tissue inflammation, characterizing obesity, 
associated or not with insulin resistance, also the adaptive immunity is indeed 
crucial. In fact, as mentioned above, in augmented adiposity, accumulation of T 
cell subsets producing IL-17, IL-22, IL-10 and interferon(IFN)-γ is detected 
[45,47-49]. Particularly, the number of IL-17- or IFN-γ-producing T cells 
positively correlated with adiposity [45,47-49]. These findings reflect some 
observations from obese mice models showing marked infiltration of both CD4+ 
and CD8+ T cells in adipose tissue, conversely to lean mice, predominantly 
characterized by a Th2- and Treg-oriented immune activation [50]. Furthermore, 
diet-induced obese mice and obese human subjects showed elevated IL-6 levels, 
which predispose to the Th17 lineage expansion, resulting in an increased 
number of IL-17-secreting CD4+ cells [24]. As mentioned above, psoriasis 
increases the risk of developing obesity but, concurrently, obesity has been 
associated with an increased prevalence and severity of psoriasis, even in 
pediatric population [6, 51,52]. The fact that obesity may aggravate psoriasis 
severity has been also confirmed by obese mice model developing exacerbated 
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psoriasis-like lesions after imiquimod induction [53]. In this model, obesity 
worsened skin lesions enhancing the expression of key-cytokines and their 
downstream gene products, particularly IL-17A, IL-22, IL-23p19, IL-17C, and β-
defensin 3 [53]. Additionally, obesity may negatively affect clinical response to 
systemic antipsoriatic treatment, and, conversely, weight loss improves psoriasis 
as well as the therapeutic response [54-56].  
Albeit some evidence suggested the potential role of pro-inflammatory psoriasis-
signature cytokines in obesity pathogenesis, and, similarly, the role of adipokines 
in psoriasis pathogenesis, the mechanisms linking psoriasis and obesity, and 
more in general metabolic syndrome, are not fully investigated. For instance, the 
association between psoriasis and adipokines is reported, though evidence 
associating psoriasis or disease severity with altered circulating adipokine levels 
is controversial. Takahashi et al. detected a significant negative correlation 
between plasma adiponectin levels and PASI score, whereas plasma leptin levels 
were enhanced with increasing PASI score, though not statistically significant 
[57]. Along these lines, TNF-α plasma concentration negatively and significantly 
correlated with plasma adiponectin levels, whereas plasma leptin levels were not 
correlated [57]. Conversely, in another study, both serum adiponectin and leptin 
levels were significantly decreased in psoriatic patients in comparison with the 
control group [58]. Other reports detected significantly lower levels of 
adiponectin and visfatin, and significantly higher levels of vaspin, omentin, 
chemerin, and resistin in psoriatic patients as compared to the control group 
[42,59-62]. Of note, a meta-analysis including nine case–control studies, 
containing 421 psoriasis patients and 348 healthy controls, revealed a 
statistically significant association between serum resistin levels and psoriasis 
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[59]. Interestingly, successful treatment of psoriasis with biologicals (i.e., 
infliximab and ustekinumab) or phototherapy (narrow band-UVB) was related to 
an increase of adiponectin serum levels and a decrease of leptin and resistin 
serum concentration [60]. Coban et al. observed higher levels of chemerin in 
patients than in controls and a strongly positive correlation between the PASI 
score and chemerin [61]. Moreover, psoriatic patients showing an improvement 
in the PASI score correlating with a significant decrease in serum leptin, omentin, 
and chemerin values, and a significant increase of serum adiponectin levels [61]. 
Conversely, Gisondi et al. found a significant decrease in the PASI score and 
serum chemerin levels, but no correlation was identified between these two 
parameters [42].  
Overall, a general agreement regarding the circulating adipokine levels and their 
pathogenic relevance in psoriasis patients needs to be defined. 
Thus, this review is aimed to provide an updated “state-of-the-art” about the 
reciprocal contribution of a small subset of conventional cytokines and 
adipokines involved in chronic inflammatory pathways, upregulated in both 
psoriasis and increased adiposity. The main effects of psoriasis-signature 
cytokines on increased adiposity as well as of adipokines on psoriasis 
pathogenesis have been summarized in Table 2. According to the current 
pathogenic model , we selected the most pathogenically relevant cytokines. IL-17 
is recognized as the key cytokine in psoriasis [63]. The main sources of IL-17 
involved in psoriasis pathogenesis, namely Th17 cells, Tc17 cells, γ/δ T cells, 
mast cells, and innate lymphoid cells (ILC)-3 also express IL-22 that 
synergistically potentiates IL-17 effects [64]. IL-23, the most potent inducer of 
IL-17/IL-22 expression, was excluded as it acts on immune cells but it does not 
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on tissue cells. Indeed, the development of psoriasis-like lesions in mice models 
induced by IL-23 is dependent on IL-17 and IL-22 activity [65]. Knockout mice 
for either IL-17 or IL-22 gene, notwithstanding stimulation with IL-23, does not 
develop tissue alterations characterizing psoriasiform lesions [65]. We also 
considered IL-6 and TNF-α as they might be classified as both psoriasis-related 
cytokines and adipokines, particularly TNF-α, representing a key cytokine in 
psoriasis pathogenesis and a crucial therapeutic target. We excluded IFN-γ as 
well as IL-12 because not pathogenically relevant. For the same reason we 
excluded other cytokines (ex., IL-9, IL-19, IL-20, IL-21, IL-24) whose role seems 
marginal. Regarding adipokines, we focused the attention on those mediators 
with pro-inflammatory or anti-inflammatory activity that had been associated 
with psoriasis. However, table 1 also included mediators (both adipokines and 
cytokines) that are not extensively discussed throughout the text. 
  
 
2.0 Role of psoriasis-signature cytokines in increased adiposity 
 
2.1 IL-17  
A pathogenic link correlating IL-17, psoriasis, and increased adiposity has been 
proposed, though IL-17 effects on adipose tissue metabolism and gene 
expression are poorly investigated.  
IL-17 is reported to have a protective role against obesity as it inhibits 
adipogenesis, reduces lipid and glucose uptake acting on both pre-adipocytes 
and adipocytes [40,41]. Particularly, IL-17 interferes with pre-adipocyte 
differentiation, downregulating the expression of C/enhancer binding protein 
D
ow
nl
oa
de
d 
by
 [8
2.5
3.1
65
.83
] a
t 2
3:3
4 2
2 J
un
e 2
01
6 
 
 
(EBP)-α and peroxisome proliferator-activated receptor gamma(PPAR)-γ, and 
inhibiting lipid uptake, but not affecting pre-adipocyte proliferation [40]. Along 
these lines, the absence of IL-17 led to the upregulation of proadipogenic 
transcription factors (CEBP-α and PPAR-γ), adipocyte-related cytokines (i.e., 
adiponectin), and genes involved in lipid and glucose metabolism [40]. Of note, in 
lean IL-17 knock-out (KO) mice, adiponectin serum levels resulted increased, 
whereas adiponectin suppression was induced by IL-17 in vivo and in vitro [40]. 
Because adiponectin is exclusively detected in mature adipocytes, the IL-17-
induced suppression highlights its anti-adipogenic activity. Notwithstanding 
these data, a positive correlation between IL-17 expression levels and increased 
adiposity was found, mirroring diet-induced obese mice showing an increased 
number of circulating IL-17-secreting CD4+ cells. Furthermore, obesity positively 
correlated with both IL-17 expression and disease severity in IL-17-driven 
inflammatory mouse models [3]. This positive correlation between obesity and 
IL-17 expression may influence psoriasis inflammation as suggested by a 
psoriasis model, wherein increased adiposity aggravates imiquimod-induced 
psoriasiform dermatitis through the increased expression of both IL-17 and IL-
22 (five-fold higher than imiquimod-treated lean controls) [53]. Thus, the 
worsening of imiquimod-induced psoriasiform dermatitis in genetically-
determined obese mice as well as in high-fat-fed obese mice, reflects the higher 
prevalence and severity of psoriasis in obese patients, and the impact on 
therapeutic response and disease severity determined by weight variation [53]. 
Overall, IL-17A is not proved to profoundly impact on obesity and metabolic 
status, as suggested by the no-protection from metabolic syndrome and no-
improvement of adipose tissue metabolism in established obesity occurring in 
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IL-17KO mice [40]. Nevertheless, IL-17 maintains its pro-inflammatory effects 
inducing adipocyte production of inflammatory mediators including IL-6, whose 
expression in adipocytes is regulated by an IL-17 signature transcription factor, 
C/EBP-β. 
2.2 IL-22  
Although adipose tissue is known to express the membrane receptor 
components, namely IL-22R1 and IL-10R2, which transduce IL-22 signals, the 
impact of IL-22 on metabolism does not seem relevant [41]. Transgenic mice 
over-expressing IL-22 did not show any significant difference compared to wild-
type mice in developing high fat diet-induced increased adiposity [41]. However, 
a significantly increased number of Th22 cells was detected in the peripheral 
blood of patients affected by obesity or diabetes, compared to healthy controls 
[21]. This could partially be explained by the increased serum level of TNF-α and 
IL-6, which are known as the major drivers of Th22 polarization [45]. 
Nevertheless, in subjects with increased adiposity compared to lean controls, a 
higher number of IL-17- and IL-22-producing CD4+ T cells infiltrating adipose 
tissue was reported [45]. This marked T cell infiltration was associated with 
increased plasma concentrations of IL-22 and IL-6 [45]. Relevantly, human 
adipose tissue CD4+ T cells co-localized with accumulating macrophages, which 
secrete IL-1β as well as other inflammatory products such as TNF-α [66]. 
Because IL-1β release is stimulated by IL-22, and IL-1β represents a key inducer 
of Th17 differentiation, a feed-forward circuit between IL-1β-producing 
macrophages and Th17 cells might be established [66].  
2.3 TNF-α  
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Physiologically, TNF-α constitutes a restraining cytokine involved in the complex 
mechanisms of adipose tissue metabolism. Accumulating macrophages in 
adipose tissue are considered the most relevant source of TNF-α, and other pro-
inflammatory molecules and their infiltration positively correlated with 
increased adiposity [67]. TNF-α stimulates adipocyte leptin synthesis [68], 
induces lipolysis and inhibits both lipogenesis and anabolic insulin-like growth 
factor 1 (IGF-1) production [43,69]. Thus, TNF-α could presumably have a 
protective role against obesity, with mechanisms limiting body mass increase. 
This evidence may, at least partially, give reason of (i) the enhanced TNF-α levels 
detected in obese subjects, with putative protective function; (ii) the body weight 
increase observed in psoriatic patients undergoing treatment with TNF-α 
inhibitors or other antipsoriatic agents decreasing TNF-α expression levels [56, 
70-72]. However, data on TNF-α role in increased adiposity are controversial as 
it may also contribute to obesity counteracting insulin receptor activity and 
inhibiting glucose transporter (GLUT)-4, with a consequent enhancement of 
insulin levels that stimulates the hunger center [68]. Notwithstanding mounting 
evidence suggesting the TNF-α contribution to insulin resistance, anti-TNF-α-
binding protein administration failed to improve insulin resistance in diabetic or 
insulin-resistant patients [73]. Likewise, anti-TNF-α therapies in non-diabetic 
psoriatic patients did not significantly vary serum concentrations of both leptin 
and resistin [74]. Overall, the ability of TNF-α blockade in dampening both 
resistin and leptin levels is still debated and controversial, albeit the anti-
inflammatory effect of anti-TNF agents is more likely associated with an 
increased body weight, positively correlating with leptin serum levels, and a 
presumable reduction of insulin resistance.  
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2.4 IL-6  
This adipo-cytokine is produced by a plethora of both immune and tissue cells 
that includes macrophages, dendritic cells, T cells, B cells, keratinocytes, 
fibroblasts, endothelial cells, and adipocytes. Particularly, it is increasingly 
expressed in inflammatory conditions such as psoriasis, in metabolic conditions 
such as obesity-associated insulin resistance [75,76]. In obesity setting, IL-6 
expression mainly derives from adipose tissue, particularly from adipocytes and 
adipose tissue-derived macrophages, contributing 33% and 20%, respectively 
[67]. In a recent study, adipose tissue-dendritic cells were also demonstrated to 
express higher levels of IL-6, as well as IL-23 and TGF-β [77].  
IL-6 has pleiotropic effects acting on a variety of cells. With regard to obesity, 
lipolysis process, and insulin resistance, its role is still debated. Nevertheless it is 
reported to (i) suppress lipoprotein lipase activity; (ii) to stimulate energy 
expenditure; (iii) to show anorexic effects suppressing appetite [78]. Because of 
its neuroendocrine activity it affects the central nervous system (i) regulating the 
hypothalamus-pituitary-adrenal axis, thus modulating cortisol release; (ii) 
stimulating liver secretion of acute-phase proteins; (iii) affecting steroid 
hormone conversion, altering sex hormone balance and therefore adipose tissue 
distribution [78, 79]. 
In a mice model, IL-6 stimulation was demonstrated to interfere with insulin 
signaling in hepatocytes, favoring insulin resistance [80]. In contrast, IL-6 
deficiency was associated with obesity and hepatic inflammation, whereas IL-6 
administration reverted insulin resistance [81]. The contrasting data on lipid and 
glucose metabolism suggest that IL-6 effects may be dependent on its tissue-
specific activity and on the localization of its increased expression [82].  
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Beside its activity in regulating insulin resistance and obesity, IL-6 is also crucial 
for linking these metabolic disorders to inflammation. A diet-induced obese 
model showed an increased number of IL-17-secreting CD4+ T cells, whose 
development was dependent on IL-6 stimulation [24]. Indeed, IL-6 KO mice on 
high-fat diet, despite developing obesity, did not show a Th17-skewed 
differentiation, indicating that obesity-induced Th17 differentiation was IL-6-
dependent [24]. Notably, adipose tissue contributes to IL-17-producing T cell 
development, through adipose-tissue dendritic cell-derived products (i.e., IL-23, 
TGF-β, and IL-6) that are involved in IL-17-producing T cell differentiation and 
expansion [77].  
 
  3.0 Role of adipokines in psoriasis inflammatory pathway  
 
3.1 Leptin  
Compared to the multitude of studies on systemic leptin effects, its role in the 
skin is poorly investigated. Leptin is mainly secreted by adipocytes and directed 
to target cells, such as epithelial cells, nervous cells and immune cells expressing 
its receptor LepR [27,83]. Indeed, leptin is known to stimulate keratinocyte 
proliferation in vitro and to act as a mitogen during skin repair in vivo [84]. In 
accordance, LepR is particularly expressed in proliferating basal layer and in 
neo-epithelial keratinocytes during skin repair [84]. It have been shown 
activation of the classical leptin pathway via JAK/STAT cascade in human HaCaT 
cells during wound repair, and induction of keratinocyte-derived pro-
inflammatory cytokines, such as IL-6, IL-8 and TNF-α [85]. In addition, leptin is 
able to alter keratinocytes redox state increasing ROS generation as well as the 
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ratio of oxidized/reduced glutathione, and AP-1 activity [86]. This could be 
linked to the effects of leptin in the psoriatic inflammatory cascade, although 
findings are controversial. Johnston et al. reported that leptin mRNA levels in 
involved and uninvolved psoriatic skin were similar to healthy controls [87]. 
However, in following studies leptin resulted highly represented in psoriatic 
skin, either in the epidermis, or in the dermis (sweat glands and hair follicles 
included) [85,88]. The authors suggested that, although leptin is involved in 
wound healing, the strong expression in psoriatic skin respect to controls might 
be due to an enhanced epidermal turnover. Conversely, multiple leptin systemic 
effects are well recognized: first of all, its pivotal role in body weight regulation 
by promoting satiety, and energy consumption [89]. Serum leptin variation 
represents a response to WAT mass increase, and leptin-deficient mice (ob/ob) 
are severely obese [90]. Leptin is not just a metabolic hormone, since it acts as a 
mediator with pleiotropic effects [27]. Indeed, as reported in obese mice, leptin 
increase is also related to several abnormalities regarding: reproduction, 
hematopoiesis, angiogenesis, bone homeostasis, lipid and glucose metabolism, as 
well as innate and adaptive immunity [90-92]. Regarding the innate immunity 
leptin is able to (i) induce the release of pro-inflammatory mediators (eg. IL-1, 
IL-6 and TNF-α) by monocytes/macrophages; (ii) enhance production of reactive 
oxygen species (ROS) by neutrophils; (iii) augment NK cell cytotoxicity. 
Moreover, leptin increases macrophage phagocytosis, neutrophil recruitment, 
NK cell activation, and promotes DC survival [27], participating to the 
antimicrobial host defense. In the context of adaptive immunity, leptin is 
involved in T cell generation, maturation and survival [93]. It mediates Th1 
phenotype differentiation by increasing IFN-γ, TNF-α and IL-2 production, while 
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it inhibits rapamycin-induced Treg cells, by increasing activation of mammalian 
target of rapamycin (mTOR), which is up-regulated in psoriatic skin as well as in 
others inflammatory skin conditions (allergic contact dermatitis and atopic 
dermatitis) [90,94]. Moreover, leptin promotes CD4+ cell differentiation into 
Th17 cells and augments IL-17A production [95]. On the other way, IL-17A also 
up-regulates leptin release by adipocytes, and the anti-leptin antibody treatment 
partially antagonizes IL-17A dependent adipogenesis inhibition [96]. 
Nonetheless, in the context of severe inflammation, leptin may also exert 
immune-suppressive functions, decreasing Th1 cytokine expression and 
reducing T cell proliferation [27]. This suggests that the effects of leptin on the 
immune system may be dependent on the specific milieu. 
3.2 Visfatin  
It was originally called pre-B cell colony-enhancing factor (PBEF) for its 
capability to augment pre-B-cell colony formation.  Only in the last decade, 
visfatin has been identified as an adipokine, produced principally by adipocytes 
and working as a bridge between adipose tissue and inflammatory mediators 
[97]. Visfatin up-regulates human monocytes and endothelial cells production of 
several mediators, either pro-inflammatory (e.i. IL-6, TNF-α and IL-1β) or anti-
inflammatory such as IL-10, IL-1 receptor antagonist (IL-1RA) [97-98]. It acts as 
chemoattractant for monocytes and lymphocytes. It is able to induce the 
expression of co-stimulatory molecules, CD80, CD40, and ICAM-1, on monocytes 
in order to increase T cell activation through a p38 and MEK mediated pathway 
[99]. Moreover, visfatin inhibits neutrophil apoptosis by caspase-3 as well as 
caspase-8-dependend mechanism [97]. All these data demonstrate that this 
adipokine has a prevalently pro-inflammatory function, further reported also in 
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human keratinocytes. Indeed, it has been demonstrated that visfatin, in 
combination with TNF-α, stimulates keratinocytes to produce several 
chemokines (CXCL8, CXCL10, and CCL20), through NF-kB and STAT3 pathway 
[100], and antimicrobial peptides (CAMP, hBD-2, hBD-3, and S100A7) [101]. This 
has also been observed in murine models of psoriasis (imiquimod-treated skin), 
where antimicrobial peptides were enhanced by visfatin [101]. Increased visfatin 
serum levels in psoriatic patients and positive correlation with Psoriasis Area 
Severity Index (PASI) have been reported [102], reflecting inflammatory state of 
these patients.  
3.3 Chemerin 
Chemerin is mostly expressed by fat tissue and liver [103], but also by epithelial 
barriers, including skin [104-106]. It is released as inactive precursor and 
converted in its active form by proteinases [107,108], in order to work as ligand 
for G protein-associated receptor chemokine-like receptor 1 (CMKLR1) [109]. 
Chemerin presents a biphasic distribution in normal skin, being over-expressed 
in the epidermis and down-regulated in the dermis [104,105]. The real function 
of chemerin in the skin is not fully clear, but it has been reported to act as 
antimicrobial protein [104,106]. Apparently, chemerin mainly works as 
chemoattractant for CMKLR1+ plasmacytoid dendritic cells (pDCs), macrophages 
and NK cells, promoting their recruitment at site of tissue damage, and 
amplifying immune response [107]. Indeed, bacteria and acute phase cytokines, 
as well as oncostatin M and IL-1β, up-regulate its production, while IL-17 and IL-
22 decrease it [110]. On the other hand, chemerin is induced by TNF-α and IL-1β, 
and its serum levels correlate with TNF-α, IL-6, and C reactive protein [111], 
suggesting that it might also act as a mediator of systemic inflammation. Indeed, 
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it has been reported high chemerin circulating levels in psoriasis and psoriatic 
arthritis patients, with decrease after infliximab therapy [42]. Moreover, 
uninvolved and involved psoriatic skin contains higher levels of chemerin than 
normal skin [112]. Accordingly, proteinases required for its activation are over-
expressed in involved psoriatic skin [112]. Chemerin is certainly considered as a 
pro-inflammatory adipokine, but its role in skin diseases needs deeper 
investigation. 
3.4  Adiponectin 
 
Adiponectin is highly expressed by mature adipocytes, but also released by 
skeletal muscle cells, cardiac myocytes, and endothelial cells [30]. Adiponectin, 
with its multiple oligomeric forms, trimer (LMW), hexamer (MMW), and the 
high-molecular weight (HMW) [30],  (i) regulates energy homeostasis, (ii) 
reduces insulin resistance and (iii) shows anti-atherogenic, anti-angiogenic, and 
anti-inflammatory functions [113].  
The effect of adiponectin on keratinocytes is yet not fully understood. It has been 
reported that it inhibits both proliferation and differentiation of keratinocytes. It 
also suppresses involucrin, TGFβ-2 and -3 expression, and decreases IL-6, IL-8, 
IL-17, IL-22, and TNF-α secretion by human keratinocytes. In psoriatic patients 
adiponectin circulating levels are decreased, compared to controls; moreover, 
they negatively correlated with PASI and the expression of pro-inflammatory 
mediators, such as IL-6 and TNF-α [114,115]. The expression of its receptor 
ADIPOR1 in psoriatic epidermis is also decreased respect to non lesional or 
healthy skin [116]. Adiponectin influences skin homeostasis also exerting 
indirect anti-inflammatory effects: (i) inhibiting TNF-α induced adhesion 
molecule expression; (ii) interfering with macrophage functions; (iii) inducing 
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IL-10 and IL-1RA by human monocytes, macrophages as well as DCs, and (iv) 
suppressing the production of IFN-γ by lipopolysaccharide (LPS)-stimulated 
human macrophages [113]. In addition, it reduces T-cell proliferation, 
macrophage phagocytic capability and macrophage TNF-α production [113]. 
Moreover, adiponectin acts as negative regulator on NK cells, suppressing their 
IL-2–augmented cytotoxic activity [117]. However, several studies have 
demonstrated that adiponectin also has pro-inflammatory effects, increasing the 
production of pro-inflammatory factors such as MMP-3, MMP-9, CCL-2, IL-8, and 
IL-6 [118-120]. It has been hyphotized that this dual function of adiponectin is 
isoform-specific: indeed, HWM adiponectin increases IL-6 production in human 
monocytes, whereas MMW isoform decreases LPS-mediated IL-6 secretion and 
also induces IL-10 release [121]. Moreover, Jung et al. suggested that adiponectin 
immunoregulatory ability works activating DCs to release pro-inflammatory 
cytokines that polarize naïve CD4+ T cells into Th1 and Th17 phenotypes [122]. 
Adiponectin enhances IL-17 expression more than IFN-γ, indicating that 
predominantly induce a Th17 response [123]. The complexity of this adipokine 
and its involvement in inflammatory skin diseases need to be elucidated. 
 
4.0 Conclusion  
The relationship between increased adiposity and psoriasis is an interesting as 
well as a challenging topic. The low but chronic grade of inflammation associated 
to increased adiposity might be involved in the development or in the 
amplification of chronic dermatoses, either through a direct interaction between 
adipocytes and keratinocytes or through the indirect modulation of the adaptive 
immune system. Adipokines are considered specific biomarkers of inflammation 
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related to increased adiposity, and they might work as a bridge between fat and 
skin in psoriasis patients (Figure 1) [124]. Indeed, in these patients, an excess of 
adipose tissue augments cardiovascular risk and might compromise the 
therapeutic response [123,125]. On the other hand, psoriasis-signature pro-
inflammatory cytokines may alter lipid metabolism, enhancing the risk of 
increased adiposity and cardiovascular diseases. However, as emerged from the 
contradictor data analyzed, the mechanism, the temporal link or the biological 
value of this “pro-inflammatory” connection between inflamed skin and 
increased adiposity require indeed further investigations. 
 
5.0  Expert commentary   
Obesity has become a worldwide epidemic health problem, that has taken 
significant attention to research aimed at understanding the biology of 
adipocytes and the events occurring in adipose tissue. Several studies show that 
increased adiposity causes chronic low-grade inflammation that promotes 
systemic metabolic dysfunction and obesity-linked disorders, such as insulin 
resistance, type 2 diabetes, atherosclerosis and ischemic heart disease. All these 
conditions not only reduce life expectancy, but also have enormous economic 
and societal impact. Increasing epidemiological findings suggests that patients 
with psoriasis have higher prevalence and incidence of obesity respect to the 
general population. Better understanding the relationship between psoriasis and 
increased adiposity is also important for delineating risk factors for all obesity-
linked disorders in these patients.  It will therefore help to improve future 
clinical studies that will include adequate adjustments for the presence of 
obesity as comorbidity among psoriatic patients. Recommendations to reduce 
D
ow
nl
oa
de
d 
by
 [8
2.5
3.1
65
.83
] a
t 2
3:3
4 2
2 J
un
e 2
01
6 
 
 
weight in obese patients with psoriasis may have favorable effects on obesity-
associated disorders as well as  on psoriasis severity. Moreover, new therapeutic 
strategies that balance pro- and anti-inflammatory adipokines levels in obese 
psoriatic patients could have a beneficial role in preventing and/or treating 
obesity-related metabolic and cardiovascular comorbidities. 
6.0 Five-year view  
Future studies are necessary to better clarify the mechanisms underlying the 
relation between increased adiposity and psoriasis. Keratinocytes as well as 
adipocytes are endocrine organ secreting multiple mediators: cytokines and 
adipokines, respectively. These represent key actors of the chronic inflammatory 
process involved both in psoriasis and obesity. The role of TNF-α is well known 
in psoriasis as well as in obesity pathogenesis and several studies have reported 
the beneficial effects of the anti-TNF-α treatment on psoriasis comorbidity, such 
as metabolic syndrome. On the contrary, while the role of IL-17 in psoriasis has 
been elucidated, controversial are the studies reported in the literature on its 
role in increased adiposity and adipose tissue homeostasis. Then, we suppose 
that this point will be more investigated in the next studies, focusing mainly on 
the impact on psoriasis comorbidity of new biologic anti-IL-17 therapies.  
7. 0 Key issues 
 Psoriasis is chronic skin disorder associated with several comorbid 
conditions, including metabolic syndrome. 
 The crosstalk between adipose tissue-derived products and psoriasis-
signature cytokines may contribute to the pathogenesis of both  psoriasis 
and metabolic syndrome. 
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 Though cytokine effects on adipose tissue are not fully elucidated and 
controversial, IL-17 as well as other cytokines alters the homeostasis of 
adipose tissue.  
 Adipokines, particularly chemerin and leptin, showing pro-inflammatory 
effects, may contribute to psoriasis pathogenesis. 
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Figure 1. Crosstalk  between skin and adipose tissue in psoriasis. 
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Psoriasis-signature cytokines, such as TNF-α, IL-17, IL-22 and IL-6, have effects 
on adipose tissue being involved in key mechanisms of lipidic metabolism, 
including increased adiposity and insulin resistance. Secreted adipokines, such 
as leptin, visfatin and chemerin have pro-inflammatory effects, amplifying the 
immune response, through Th17 and Th1; whereas adiponectin shows anti-
inflammatory effects. Moreover, high circulating levels of leptin, visfatin and 
chemerin have been reported in psoriatic patients, whereas adiponectin is 
decreased. In the plaque an enhancement of leptin and chemerin protein 
expression has been found. 
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Table I. Main features of relevant adipokines and cytokines. 
 
Adipokines                    Main role Site of production
Adipokines with prevalent hormonal activity 
Leptin Stimulates satiety, lipolysis, glucose and lipid 
metabolism, enhances insulin sensitivity [27] 
Adipocyte
Visfatin Enhances insulin sensitivity, induces lipogenesis [28] Adipocyte
Chemerin Stimulates adipogenesis and insulin resistance [29] Adipocyte
Adiponectin Regulates glucose metabolism, enhances insulin 
sensitivity [30] 
Adipocyte
Resistin Induces insulin resistance  [31] Adipocyte, macrophage
  
Adipsin Inhibits lipolysis [32] Adipocyte, macrophage
Apelin Inhibits insulin secretion [33] Adipocyte, macrophage
  
Vaspin Enhances insulin resistance [34] Adipocyte
Omentin Modulates insulin activity [32] Macrophage
Lipocalin 2 Induces insulin sensitivity [32] Adipocyte, macrophage
  
Retinol binding protein 4 Induces insulin resistance [35] Adipocyte
 
Adipo-cytokines involved in inflammatory response 
IL-6 
 
Pro-inflammatory cytokines; stimulates lipolysis, 
reduces insulin and leptin activity [36] 
Adipocyte, macrophage, 
TNF-α 
 
Pro-inflammatory cytokines; stimulates lipolysis, 
induces insulin resistance [36] 
endothelial stromal cell
Adipocyte, macrophage 
sTNF-RII Pro-inflammatory cytokines; stimulates lipolysis, 
induces insulin resistance [37] 
 
Adipocyte, macrophage 
  
IL-1RA Anti-inflammatory cytokines; reduces insulin 
sensitivity [38] 
Macrophage
IL-10 Anti-inflammatory cytokine [38] Adipocyte, macrophage
IL-8 Pro-inflammatory chemokine [32] Endothelial stromal cell
  
MCP-1 Pro-inflammatory chemokine; stimulates lipolysis, 
induces insulin resistance [33] 
Adipocyte, macrophage
  
Adipokines with vascular activity 
PAI-1 Pro-thrombotic activity, enhances insulin resistance
[39] 
Endothelial stromal cell
 
Adipokines with lipid metabolism activity 
FABP-4 Regulates fatty acid transport [34] Adipocyte
  
Adipokines with enzymatic activity 
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Cathepsin S Degrades elastin and induces atherosclerosis [32] Adipocyte, macrophage
GPX-3 Has anti-oxidant activity [38] Adipocyte
  
ACE Converses angiotensisn I into angiotensin II [38] Endothelial stromal cell
Adipokine as acute phase protein 
CRP Stimulates cytokine and adhesion molecule expression
[36] 
Adipocyte
  
SAA Stimulates monocyte chemotaxis and adhesion 
molecule expression [34] 
Adipocyte
 
Psoriasis-signature cytokines involved in lipid and glucose metabolism 
  
IL-17 
 
Inhibits adipogenesis, reduces lipid and glucose uptake 
[40,41] 
CD4+ T cells, CD8+ T cells, 
innate lymphoid cells 3, mast 
cells, neutrophils, γδ T cells  
TNF-α Presumably plays a protective role against obesity [43,44] 
Adipose tissue cells,   
dendritic cells, endothelial 
cells,  fibroblasts, 
keratinocytes, macrophages, 
mast cells, neutrophils, T cells 
IL-6 Suppresses lipoprotein lipase activity; stimulates energy expenditure; drive Th17 development [45] 
Adipose tissue cells, 
keratinocytes,endothelial 
cells, fibroblasts, 
macrophages, dendritic cells, 
T cells 
  
IL-22 
 
Role in obesity and insulin resistance to be defined 
[40,45] 
CD4+ T cells, CD8+ T cells,  γδ
T cells, innate lymphoid cells 
3,  mast cells 
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Table 2. Main effects of psoriasis-signature cytokines on increased 
adiposity as well as of adipokines on psoriasis pathogenesis. 
 
PASI, Psoriasis Area Severity Index 
IL, interleukin 
TNF, tumor necrosis factor 
ADIPOR, adiponectin receptor 
 
Psoriasis-signature cytokines Increased adiposity 
IL-17 
• inhibits adipogenesis [40,41] 
• reduces lipid and glucose uptake [40,41] 
• suppresses adiponectin production [40] 
• correlates positively with increased adiposity [3,53] 
• induces adipocyte production of IL-6 [40] 
IL-22 
• high number of IL-22-producing CD4+ T cells infiltrating 
adipose in increased adiposity [45] 
TNF-α 
• induces lipolysis and inhibits lipogenesis [43] 
• stimulates adipocyte leptin synthesis [68]  
• contributes to insulin resistance [68] 
IL-6 
• suppress lipoprotein lipase activity [78] 
• stimulates energy expenditure [78] 
• show anorexic effects suppressing appetite [78] 
• favors insulin resistance [80] 
Adipokines Psoriasis 
Leptin  
• high circulating levels in psoriasis patients [88] 
• mRNA levels in involved and uninvolved psoriatic skin are 
similar to healthy controls [87] 
• protein levels are enhanced in psoriatic skin [85,88] 
Visfatin 
• high serum levels in psoriatic patients and positive correlation 
with PASI [102] 
Chemerin 
• high circulating levels in psoriasis and psoriatic arthritis 
patients, with decrease after infliximab therapy [42] 
• high protein levels in uninvolved and involved psoriatic skin 
[112] 
Adiponectin 
• circulating levels are decreased in psoriatic patients and 
negatively correlate with PASI and the expression of IL-6 and 
TNF-α [114,115] 
• the expression of its receptor ADIPOR1  is decreased in psoriatic 
epidermis [116] 
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